PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).

Autor:	Miricescu D; Department of Biochemistry, Faculty of Dental Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Balan DG; Discipline of Physiology, Faculty of Dental Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Tulin A; Department of Anatomy, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of General Surgery, 'Prof. Dr. Agrippa Ionescu' Clinical Emergency Hospital, 011356 Bucharest, Romania., Stiru O; Department of Cardiovascular Surgery, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Cardiovascular Surgery, 'Prof. Dr. C. C. Iliescu' Emergency Institute for Cardiovascular Diseases, 022322 Bucharest, Romania., Vacaroiu IA; Department of Nephrology and Dialysis, 'Sf. Ioan' Emergency Clinical Hospital, 042122 Bucharest, Romania.; Department of Nephrology, Nutrition and Metabolic Diseases, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Mihai DA; Discipline of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department II of Diabetes, 'Prof. N. Paulescu' Nutrition and Metabolic Diseases National Institute of Diabetes, 020474 Bucharest, Romania., Popa CC; Department of Surgery, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Surgery, Emergency University Hospital, 050098 Bucharest, Romania., Papacocea RI; Discipline of Physiology, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Enyedi M; Department of Anatomy, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Radiology, 'Victor Babes' Private Medical Clinic, 030303 Bucharest, Romania., Sorin NA; Division of Urology, 'Prof. Dr. Agrippa Ionescu' Clinical Emergency Hospital, 011356 Bucharest, Romania., Vatachki G; Department of General Surgery, 'Fundeni' Clinical Institute 022328 Bucharest, Romania., Georgescu DE; Department of Surgery, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Nica AE; Department of Orthopedics, Anesthesia Intensive Care Unit, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Stefani C; Department of Family Medicine and Clinical Base, Dr. Carol Davila Central Military Emergency University Hospital, 010825 Bucharest, Romania.
Jazyk:	angličtina
Zdroj:	Experimental and therapeutic medicine [Exp Ther Med] 2021 May; Vol. 21 (5), pp. 540. Date of Electronic Publication: 2021 Mar 23.
DOI:	10.3892/etm.2021.9972
Abstrakt:	Renal cell carcinoma (RCC) accounts for over 90% of all renal malignancies, and mainly affects the male population. Obesity and smoking are involved in the pathogenesis of several systemic cancers including RCC. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway regulates cell growth, differentiation, migration, survival, angiogenesis, and metabolism. Growth factors, hormones, cytokine and many extracellular cues activate PI3K/AKT/mTOR. Dysregulation of this molecular pathway is frequently reported in human cancers including RCC and is associated with aggressive development and poor survival rate. mTOR is the master regulator of cell metabolism and growth, and is activated in many pathological processes such as tumour formation, insulin resistance and angiogenesis. mTOR inhibitors are used at present as drug therapy for RCC to inhibit cell proliferation, growth, survival, and the cell cycle. Temsirolimus and everolimus are two mTOR inhibitors that are currently used for the treatment of RCC. Drugs targeting the PI3K/AKT/mTOR signalling pathway may be one of the best therapeutic options for RCC. Competing Interests: The authors declare that they have no competing interests. (Copyright: © Miricescu et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu